Cargando…

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients

Background and Objectives: One of the most frequently mutated oncogenes in cancer belongs to the Ras family of proto-oncogenes, which encode distinct key signaling events. RAS gain-of-function mutations are present in ~30% of all human cancers, with KRAS being the most frequently mutated isoform sho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aran, Veronica, Zalis, Mariano, Montella, Tatiane, de Sousa, Carlos Augusto Moreira, Ferrari, Bruno L., Gil Ferreira, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539053/ https://www.ncbi.nlm.nih.gov/pubmed/34684076 http://dx.doi.org/10.3390/medicina57101039

Ejemplares similares

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients
por: Gil Ferreira, Carlos, et al.
Publicado: (2014)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
por: Cafiero, Concetta, et al.
Publicado: (2020)

EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
por: Montella, Tatiane, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Imaging of synchronous multiple primary lung adenocarcinoma with concomitant EGFR and KRAS mutations: a case report and review of the literature
por: Ma, Jing-Wen, et al.
Publicado: (2021)

Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation
por: Yang, Shifeng, et al.
Publicado: (2018)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status
por: Hsu, Jim, et al.
Publicado: (2022)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
por: Rekhtman, Natasha, et al.
Publicado: (2013)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma
por: Wen, Sara W. C., et al.
Publicado: (2020)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS‐mutated lung adenocarcinoma
por: Li, Hong‐Shuai, et al.
Publicado: (2023)

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
por: Vaclova, Tereza, et al.
Publicado: (2022)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma
por: Elghissassi, Ibrahim, et al.
Publicado: (2014)

Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
por: Hu, Yan, et al.
Publicado: (2020)

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
por: Schluckebier, Luciene, et al.
Publicado: (2020)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma
por: De Falco, Elena, et al.
Publicado: (2021)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations
por: Leal, Letícia Ferro, et al.
Publicado: (2019)

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma
por: Park, Jangchul, et al.
Publicado: (2016)

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis
por: Lohinai, Zoltan, et al.
Publicado: (2017)

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
por: Bournet, Barbara, et al.
Publicado: (2016)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
por: TAKAMOCHI, KAZUYA, et al.
Publicado: (2013)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Morphological and Molecular Characterization of KRAS G12C-Mutated Lung Adenocarcinomas
por: Pirlog, Radu, et al.
Publicado: (2022)

Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
por: Peng, Xinyi, et al.
Publicado: (2023)

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
por: Lee, Taebum, et al.
Publicado: (2016)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
por: Hafezi, Shirin, et al.
Publicado: (2021)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9p6uos29d0q80hokj8e5m4hnb